Compare SECZ & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SECZ | AMPH |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2026 | 2005 |
| Metric | SECZ | AMPH |
|---|---|---|
| Price | $13.95 | $25.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | $13.94 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 3.6M | 418.3K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $16.24 | $3.87 |
| Revenue Next Year | $72.48 | $4.90 |
| P/E Ratio | ★ N/A | $33.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.14 | $16.65 |
| 52 Week High | $17.00 | $29.52 |
| Indicator | SECZ | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 61.99 |
| Support Level | $5.86 | $18.51 |
| Resistance Level | N/A | $29.40 |
| Average True Range (ATR) | 1.42 | 1.00 |
| MACD | 0.39 | 0.08 |
| Stochastic Oscillator | 75.81 | 51.04 |
Securitize Holdings Inc provides a platform for tokenized real-world assets specializing in tokenizing real-world assets (RWAs) like funds, equities, and fixed income on blockchain networks. The company operates across two primary verticals: i) Tokenization: It consists of on-chain infrastructure and tokenization & distribution, ii) Asset Servicing: It covers post-issuance transfer agent and fund management services. The majority of the company's revenue is derived from the Tokenization vertical.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.